Articles tagged "Kidney transplantation"

2019 American Transplant Congress
Multicenter Cohort Study of Frailty and Access to Kidney Transplantation
C. Haugen¹, N. Chu¹, H. Ying¹, N. Desai¹, S. Norman², J. Garonzik-Wang¹, A. Bingaman³, D. Segev¹, M. McAdams-DeMarco¹
¹JHU, Baltimore, MD, ²MIchigan, Ann Arbor, MI, ³Methodist, San Antonio, TX
*Purpose: Frailty, a syndrome distinct from comorbidity and disability, is clinically manifested as a decreased resistance to stressors and is present in up to 35%…
2019 American Transplant Congress
Vo_2peakSuperior to Current Established Measure of Post Kidney Transplant Survival Score (EPTS Score)
H. Chakkera¹, R. Butterfield¹, M. Buras¹, B. Kaplan²
¹Mayo Clinic Hospital, Phoenix, AZ, ²Baylor Scott and White, Dallas, TX
*Purpose: The Scientific Registry of Transplant Recipients (SRTR) utilizes the calculated estimated posttransplant survival (EPTS) score as the measure of post kidney transplant survival to…
2019 American Transplant Congress
Early CXCR5⁺PD1⁺ICOS⁺Circulating Follicular T Helpers Are Associated with De Novo Donor-Specific Anti-HLA Antibodies after Renal Transplantation
R. Danger¹, M. Chesneau¹, F. Delbos², S. Lebot¹, C. Kerleau¹, A. Chenouard¹, A. Cesbron², M. Giral³, S. Brouard³
¹CRTI- INSERM UMR 1064- ITUN- Labex IGO -Université de Nantes -CHU Nantes, Nantes, France, ²Laboratoire Histocompatibilité et Immunogénétique - Etablissement Français du sang, Nantes, France, ³Centre d’Investigation Clinique en Biothérapie, Centre de ressources biologiques, Fondation Centaure, CRTI- INSERM UMR 1064- ITUN- Labex IGO -Université de Nantes -CHU Nantes, Nantes, France
*Purpose: Donor specific anti-HLA antibodies (DSA) are a major risk factor associated with renal allograft outcome. As a trigger of B cell antibody production, T…
2019 American Transplant Congress
After 10 Years: The Results of HLA Mismatched Combined Kidney and Bone Marrow Transplantation for Renal Allograft Tolerance
T. Kawai¹, D. H. Sachs¹, T. Spitzer¹, N. Tolkoff-Rubin¹, R. B. Colvin¹, N. Elias¹, M. Sykes², A. Cosimi¹
¹Massachusetts General Hospital, Boston, MA, ²Columbia University, NYC, NY
*Purpose: Based on decades-long basic studies in animal models, we have applied combined kidney and donor bone marrow transplantation (CKBMT) for induction of allograft tolerance…
2019 American Transplant Congress
Differential Expression of B Cell Activating Factor in Experimental Models of Acute and Chronic Active Antibody-Mediated Rejection
S. Reese, N. Wilson, L. Ptak, R. Redfield, A. Djamali, S. E. Panzer
University of Wisconsin Madison, Madison, WI
*Purpose: The B cell survival cytokine, BAFF [B cell activating factor], promotes B cell maturation and is a marker of disease activity in a variety…
2019 American Transplant Congress
Evaluating Adherence to Immunosuppressive Drugs through Trackyourmed® an Innovative Qr Code-Scanner App in Renal Transplantation: Preliminary Results from i-COM Trial
E. Melilli¹, M. Meneghini¹, N. Montero¹, A. Coloma¹, I. Revuelta², F. Moreso³, V. Torregrosa², J. Grinyo¹, O. Bestard¹
¹Renal Transplant Unit, Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain, ²Renal Transplant Unit, Hospital Clinic, Barcelona, Spain, ³Renal Transplant Unit, Vall D'Hebron Hospital, Barcelona, Spain
*Purpose: Low adherence to chronic immunosuppressive (IS) drugs has been recognized as a major cause of premature graft loss. Although erratic trough blood IS levels…
2019 American Transplant Congress
Transcriptional Changes in PBMC Associated with Development of Infection and Rejection in Older and Younger Kidney Transplant Recipients
J. Schaenman¹, M. Rossetti², E. Liang¹, O. E. Beaird¹, S. Bunnapradist³, E. F. Reed², S. Cole⁴
¹Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Changes in immune response are central to vulnerability to infection and rejection, especially for the growing numbers of older kidney transplant recipients. We sought…
2019 American Transplant Congress
Impact of Extremely Prolonged Cold Ischemia Time in Combination with AKI on Kidney Transplantation Outcome – A Single Center Experience
N. Sharma, Z. Haddad, Y. Qazi
USC, Los Angeles, CA
*Purpose: Donor kidneys with prolonged cold ischemia time (CIT) and acute kidney injury (AKI) are often rejected on the view they do not achieve successful…
2019 American Transplant Congress
Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 10 Years Follow-Up
Y. Watarai¹, S. Narumi¹, T. Tomosugi¹, K. Futamura², M. Okada¹, M. Tsujita², T. Hiramitsu¹, T. Kobayashi³, N. Goto²
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan, ²Transplant Nephrology, Nagoya Daini Red Cross Hospital, Nagoya, Japan, ³Kidney Transplantation, Aichi Medical University, Nagoya, Japan
*Purpose: Long-term efficacy and safety of everolimus (EVR) based immunosuppression for de novo kidney transplant recipient who were involved in A1202 study from our institute…
2019 American Transplant Congress
Combination of Extended-Release Tacrolimus Plus Everolimus Once Daily in De Novo Kidney Transplant Recipients: ER-Tac vs LCPT
G. Spagnoletti, M. P. Salerno, F. De Gennaro, J. Romagnoli, F. Citterio
Surgery, Renal Transplant Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
*Purpose: Combination of Everolimus (EVR) with Tacrolimus (Tac) permits reduced calcineurin inhibitors exposure and, recently, has been demonstrated safe and effective. Two different once-daily Tacrolimus…